| ISIN | US26922A8264 |
|---|---|
| TER | 0.01% |
| Replication | Synthetic |
| Distribution | Accumulating |
| Launch Year | 2015 |
| AUM | $0.01 billion |
| Provider | Range Cancer |
| Exchange | USA Stocks (USA) |
| Currency | USD |
| Country | USA |
| Type | ETF |
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ("ADRs") with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund"s total assets will be invested in the component securities of the index.
Consult fund provider.
| Period | Return (%) |
|---|---|
| 1 Month | -4.16% |
| 3 Months | -27.89% |
| 6 Months | -32.90% |
| 1 Year | -33.92% |
| 3 Years | -35.18% |
| 5 Years | -64.56% |
| Since Inception | -60.90% |
Distribution: Accumulating
Volatility and risk metrics are calculated based on historical price movements.
This ETF is widely available on major European brokers like Trade Republic, Scalable, and DEGIRO.
Compare brokers →Exchange: USA Stocks (USA)
Currency: USD
Is this ETF accumulating?
Yes, it reinvests dividends.